Loading clinical trials...
Loading clinical trials...
An Extension Multicenter Phase II Open Label Non-comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer.
Conditions
Interventions
docetaxel (XRP6976)
Locations
1
Japan
Sanofi-Aventis Administrative Office
Tokyo, Japan
Start Date
May 1, 2005
Primary Completion Date
September 1, 2008
Completion Date
September 1, 2008
Last Updated
October 1, 2009
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions